The federal agencies responsible for regulating financial relationships among oncology providers had a busy year in 2008. In the past year, the Centers for Medicare & Medicaid Services (CMS) issued new Stark Law rules, and the Office of the Inspector General (OIG) issued Advisory Opinion 08-10, which may adversely impact certain collaborative ventures among oncology providers. In 2008, CMS also adopted new anti-mark-up rules and new standards for independent diagnostic testing facilities (IDTFs, which are Medicare-certified imaging facilities) that may also adversely affect certain collaborative arrangements among oncology providers and suppliers. These regulatory changes will affect certain:
Read the complete article by clicking on the link below.